Five-in-One Vaccine Microneedle Patch for Diphtheria, Tetanus, Pertussis, Hepatitis B, and Haemophilus influenzae Type b
Author Information
Author(s): Choi In-Jeong, Cha Hye-Ran, Kwon Danbi, Kang Aram, Kim Ji Seok, Kim Jooyoung, Choi Jeong-Eun, Chung Hyeon Woo, Park Sunghoon, Shim Doo Hee, Kim Tae-Hyun, Baek Seung-Ki, Na Woon-Sung, Lee Jae Myun, Park Jung-Hwan, Skalko-Basnet Natasa
Primary Institution: QuadMedicine R&D Centre, QuadMedicine, Inc.
Hypothesis
Can a five-in-one vaccine microneedle patch improve vaccine delivery and stability?
Conclusion
The five-in-one MN patch maintains stable antigenicity for up to 12 months and shows immunological efficacy comparable to traditional intramuscular injections.
Supporting Evidence
- The five-in-one MN patch demonstrated stable antigenicity for up to 12 months at room temperature.
- In animal studies, the patch induced antibody titers comparable to traditional IM injections for all vaccines.
- Immunogenic responses to Pertussis and Hib vaccines via microneedles were reported for the first time.
- The patch allows for simultaneous yet independent delivery of vaccines.
Takeaway
This study created a special patch that can deliver five vaccines at once, making it easier and more effective to vaccinate people.
Methodology
The patch was tested for long-term stability and evaluated for immunogenicity in mice and minipigs, measuring antibody titers using ELISA.
Limitations
The study lacks accelerated stability testing and freeze-thaw cycle evaluations.
Participant Demographics
Mice and minipigs were used for testing.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website